Search Bar & Filters
Found 26 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are evaluating the effectiveness of combination antibiotic therapy compared to single antibiotic therapy for adults hospitalized with Staphylococcus aureus bloodstream infections. This study focuses on patients identified as high-risk early in their infection and aims to determine if combination therapy improves outcomes compared to monotherapy. Both methicillin-sensitive and methicillin-resistant bacterial infections are included. The trial is a randomized, crossover Phase 4 study conducted in hospitals. Participants with methicillin-sensitive Staphylococcus aureus bacteremia MSSAB will receive either a single intravenous beta-lactam antibiotic cefazolin or nafcillin or combination therapy including that beta-lactam plus ertapenem. Those with methicillin-resistant Staphylococcus aureus bacteremia MRSAB will be treated with either monotherapy of vancomycin or daptomycin or combination therapy with daptomycin plus ceftaroline. Treatment assignments alternate monthly by hospital. Low-risk patients receive usual care without randomization. During the study, participants will be monitored from enrollment through 30 and 90 days for various outcomes including a desirability of outcome ranking, hospital-free days alive, mortality rates, bacteremia-free days, hospital length of stay, direct hospital costs, antibiotic costs, antibiotic-associated adverse events, and Clostridioides difficile infections. Data from all hospitalized patients with SAB at participating hospitals will be analyzed. The study is expected to complete in January 2029.
Actively Recruiting
Researchers are studying colorectal cancer incidence in people aged 45 to 70 who have 1 to 2 small, non-advanced adenomas found on colonoscopy. The trial compares two surveillance strategies performing follow-up colonoscopies at both 5 and 10 years versus only at 10 years. The goal is to better understand the timing and benefit of surveillance colonoscopy for this common condition, as current guidelines vary and lack strong randomized evidence. Participants are randomly assigned to receive either a surveillance colonoscopy at 5 and 10 years or at 10 years only after their qualifying colonoscopy. The colonoscopies will follow current quality guidelines, with all polyps completely removed during the initial exam. Standard preparation instructions will be given before each colonoscopy. This study aims to provide clear evidence on the best interval for surveillance after detecting non-advanced adenomas. During the study, participants will be monitored for colorectal cancer development over 10 years, which is the primary outcome measure. Follow-up includes scheduled colonoscopies and any necessary unscheduled procedures according to clinical need. The study will collect data on cancer incidence to guide future clinical recommendations. Participants will be followed until the study ends with safety and health closely observed throughout their participation.
Actively Recruiting
Researchers are evaluating whether high-dose gabapentin can reduce the need for opioid pain medications in patients undergoing chemotherapy and radiation for squamous cell carcinoma of the head and neck. Oral mucositis, a painful side effect of radiation, often requires opioid treatment which can cause many side effects and long-term use concerns. This phase III trial aims to see if gabapentin can better manage mucositis pain compared to placebo. Participants are randomly assigned to receive either gabapentin or a placebo starting at the eighth radiation treatment. Both groups receive standard chemotherapy, radiation, and pain care. Gabapentin or placebo is given orally once daily on day 1, twice daily on day 2, and three times daily from day 3 onward. Treatment continues until mucositis symptoms improve and other pain medications stop, followed by a gradual dose reduction over 11 days. Blood samples are collected throughout. During the study, participants opioid use, pain levels, and quality of life are regularly assessed. Follow-up visits occur at 4 weeks, 3 months, and 6 months after chemoradiation ends. Researchers monitor pain scores, opioid use duration, adverse effects, feeding tube needs, and other health measures to understand gabapentins impact on pain and treatment outcomes.
Actively Recruiting
Researchers are studying how certain factors like age, gender, other medical conditions, and the type of immunotherapy affect whether patients with malignant solid tumors develop mild or serious side effects from immune checkpoint inhibitor treatments. This observational study aims to develop and validate a model that predicts severe immune-related side effects during the first year of immunotherapy, while also assessing quality of life and adverse events over 12 months. The study is sponsored by the SWOG Cancer Research Network and includes translational medicine goals such as evaluating cytokine levels as predictors and establishing a tissue and blood sample repository. Participants will provide a tissue sample at the start of their routine cancer treatment and complete questionnaires at multiple time points at treatment start, and weeks 4, 12, 24, and 52. They may also provide optional blood samples during the study. This design allows researchers to monitor immune-related side effects and patient-reported outcomes over time. During the study, participants will complete various questionnaires to report their quality of life, cognitive function, and side effects. Blood and tissue samples will be analyzed to explore predictive markers of toxicity. Researchers will track the occurrence of severe immune-related side effects over 52 weeks and assess changes in patient-reported outcomes. The study includes ongoing monitoring and data collection, with participation lasting approximately one year from treatment start.
Actively Recruiting
Researchers are comparing durvalumab immunotherapy to the usual post-surgery observation approach for people with early-stage non-small cell lung cancer who have no remaining cancer cells after standard treatment. This phase III trial focuses on patients with stage II to IIIB disease who achieved a complete response following neoadjuvant chemo-immunotherapy. The study aims to find out whether durvalumab can help patients live longer and prevent cancer from coming back compared to just monitoring after surgery. Participants are randomly assigned to one of two groups. One group receives durvalumab intravenously once every 28 days for up to 12 cycles, provided there is no disease progression or unacceptable side effects. The other group undergoes active surveillance without additional treatment for 12 months. During the trial, all participants have regular CT scans and blood samples taken. After treatment or surveillance, patients are followed annually for up to 10 years. Throughout the study, participants complete questionnaires assessing quality of life and symptoms. Researchers monitor disease-free survival, overall survival, and adverse events up to 10 years after randomization. The trial also collects specimens and images for future research. Participants have regular visits for scans, blood tests, and assessments to evaluate the safety and effects of durvalumab compared to observation.
Actively Recruiting
Researchers are evaluating the side effects and effectiveness of adding inotuzumab ozogamicin to frontline chemotherapy for young adults aged 18 to 39 with newly diagnosed B acute lymphoblastic leukemia, a type of blood cancer. Inotuzumab ozogamicin is a targeted therapy that delivers a chemotherapy drug directly to cancer cells. This phase III trial aims to confirm the safety and improve event-free survival compared to standard pediatric-inspired chemotherapy. Participants receive a combination of chemotherapy drugs in several treatment courses, including remission induction, remission consolidation, interim maintenance, delayed intensification, and maintenance therapy. Those in the experimental group receive inotuzumab ozogamicin intravenously on specific days alongside chemotherapy, with additional treatments like blinatumomab given if minimal residual disease is detected. Procedures such as bone marrow biopsies and imaging are performed throughout. Participants will be closely monitored through blood tests, bone marrow samples, imaging scans, and symptom assessments. Researchers will measure outcomes like event-free survival, disease-free survival, overall survival, response rates, and adverse events over several years. After treatment, participants are followed regularly for up to 10 years to assess long-term effects and survival.
Actively Recruiting
Researchers are studying patients with high-risk smoldering multiple myeloma to compare how well lenalidomide and dexamethasone work with or without daratumumab in treating this condition. The trial aims to assess overall survival, progression-free survival, response rates, safety, and quality of life among participants, while also exploring treatment adherence and disease markers over time. Participants are randomly assigned to one of two groups. One group receives daratumumab intravenously on a set schedule along with oral lenalidomide daily and oral dexamethasone on specified days in 28-day treatment cycles for up to 24 courses. The other group receives only oral lenalidomide and dexamethasone on a similar 28-day cycle schedule for the same duration, unless disease progression or unacceptable side effects occur. Throughout the study, participants will undergo regular assessments including blood tests, bone marrow biopsies, imaging scans, and questionnaires to monitor disease status, treatment effects, and quality of life. Follow-up visits will continue every 3 to 12 months for up to 15 years after study treatment ends to track long-term outcomes. Researchers will measure survival, symptom changes, adverse events, and minimal residual disease levels to evaluate treatment impact.
Actively Recruiting
Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.
1-10 of 26
1